Table 3 Patient demographics and baseline characteristics prior to TACE
TACE patients (N = 572) | |
|---|---|
Median age, years (range) | 62 (20–88) |
Sex, n (%) | |
Male | 411 (72) |
Female | 161 (28) |
Disease characteristics, n (%)a | |
Ascites | 94 (16) |
Distant metastases | 36 (6) |
Portal vein thrombosis | 29 (5) |
Encephalopathy | 4 (1) |
General medical history, n (%)b | |
Hypertension | 294 (51) |
Diabetes | 195 (34) |
Potential etiology of HCC, n (%)b | |
Alcoholic cirrhosis | 123 (22) |
Non-alcoholic cirrhosis | 425 (74) |
HCV | 217 (38) |
HBV | 39 (7) |
Viral hepatitis, unspecified | 17 (3) |
Prior (non-TACE) treatment of HCC, n (%)b | |
Chemotherapy | 45 (8) |
Sorafenib | 23 (4) |
Liver resection | 8 (1) |
Percutaneous ethanol injection | 3 (1) |
Radioembolization by Y90 | 3 (1) |
Liver transplantation | 0 |
Radiofrequency ablation | 0 |